Screener
CRISPR Therapeutics CRSP Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Loss from operations | (130,248) | (148,424) |
| Other income: | ||
| Other income, net | 8,156 | 13,537 |
| Total other income, net | 8,156 | 13,537 |
| Net loss before income taxes | (122,092) | (134,887) |
| Provision for income taxes | (839) | (1,109) |
| Net loss | (122,931) | (135,996) |
| Foreign currency translation adjustment | (32) | 41 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's other income (expense)?
- CRISPR Therapeutics (CRSP) reported other income (expense) of $8.16M in Q1 2026.
- How has CRISPR Therapeutics's other income (expense) changed year-over-year?
- CRISPR Therapeutics's other income (expense) decreased by 39.8% year-over-year, from $13.54M to $8.16M.
- What is the long-term trend for CRISPR Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's other income (expense) has grown at a 94.9% compound annual growth rate (CAGR), from $6M to $86.61M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about CRISPR Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude